Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lebbé C[au]:

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. Wolchok JD et al. N Engl J Med. (2017)

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. Weber J et al. N Engl J Med. (2017)

Merkel cell carcinoma. Becker JC et al. Nat Rev Dis Primers. (2017)

Search results

Items: 1 to 50 of 363

1.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N.

J Clin Oncol. 2019 Oct 14:JCO1800794. doi: 10.1200/JCO.18.00794. [Epub ahead of print]

PMID:
31609670
2.

Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?

Delyon J, Lourenço N, Vu LT, Allayous C, Baroudjian B, Lebbe C.

J Clin Oncol. 2019 Oct 9:JCO1901891. doi: 10.1200/JCO.19.01891. [Epub ahead of print] No abstract available.

PMID:
31596635
3.

Stage IV cutaneous squamous cell carcinoma (cSCC): treatment outcomes in a series of 42 patients.

Chapalain M, Baroudjian B, Dupont A, Lhote R, Lambert J, Bagot M, Lebbe C, Basset-Seguin N.

J Eur Acad Dermatol Venereol. 2019 Oct 6. doi: 10.1111/jdv.16007. [Epub ahead of print]

PMID:
31587382
4.

[Creation, implementation and objectives of CARADERM, a national network for rare skin carcinomas - Adnexal neoplasm part].

Seris A, Battistella M, Beylot-Barry M, Dalle S, Mortier L, Lebbé C, Blom A, Neidhart-Berard EM, Kramkimel N, Dupuy A, Zehou O, Dalac S, Jullie ML, Cribier B, Jouary T; Pour CARADERM, réseau de cancers rares dermatologiques (www.caraderm.org); le Groupe de cancérologie cutanée de la Société française de dermatologie.

Ann Dermatol Venereol. 2019 Sep 30. pii: S0151-9638(19)30287-X. doi: 10.1016/j.annder.2019.07.006. [Epub ahead of print] French.

PMID:
31582261
5.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

PMID:
31562797
6.

Baseline Genomic Features in BRAFV600-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care.

Louveau B, Jouenne F, Reger de Moura C, Sadoux A, Baroudjian B, Delyon J, Herms F, De Masson A, Da Meda L, Battistella M, Dumaz N, Lebbe C, Mourah S.

Cancers (Basel). 2019 Aug 18;11(8). pii: E1203. doi: 10.3390/cancers11081203.

7.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ.

Ann Oncol. 2019 Aug 13. pii: mdz221. doi: 10.1093/annonc/mdz221. [Epub ahead of print] No abstract available.

PMID:
31406976
8.

Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial.

Eggermont AMM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, Weber JS, Maio M, Hosein F, de Pril V, Kicinski M, Suciu S, Testori A.

Eur J Cancer. 2019 Sep;119:1-10. doi: 10.1016/j.ejca.2019.07.001. Epub 2019 Aug 7.

PMID:
31400634
9.

Atypical BRAF and NRAS Mutations in Mucosal Melanoma.

Dumaz N, Jouenne F, Delyon J, Mourah S, Bensussan A, Lebbé C.

Cancers (Basel). 2019 Aug 8;11(8). pii: E1133. doi: 10.3390/cancers11081133. Review.

10.

Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.

Toulmonde M, Pulido M, Ray-Coquard I, Andre T, Isambert N, Chevreau C, Penel N, Bompas E, Saada E, Bertucci F, Lebbe C, Le Cesne A, Soulie P, Piperno-Neumann S, Sweet S, Cecchi F, Hembrough T, Bellera C, Kind M, Crombe A, Lucchesi C, Le Loarer F, Blay JY, Italiano A.

Lancet Oncol. 2019 Sep;20(9):1263-1272. doi: 10.1016/S1470-2045(19)30276-1. Epub 2019 Jul 19.

PMID:
31331699
11.

Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series.

Lemasson J, Cuzzubbo S, Doucet L, Gounant V, Baroudjian B, Herms F, Carpentier AF, Lebbé C, Vitaux H, Hautefort C, Delyon J; PATIO group.

Eur J Cancer. 2019 Aug;117:116-118. doi: 10.1016/j.ejca.2019.05.022. Epub 2019 Jul 3. No abstract available.

PMID:
31279302
12.

Challenges in the diagnosis of primary cutaneous CD30+ anaplastic large-cell lymphoma.

Dobos G, Battistella M, Jouenne F, Mourah S, Vignon-Pennamen MD, Ram-Wolff C, Herms F, Dauendorffer JN, Rivet J, Cayuela JM, Bouaziz D, Brice P, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jul 6. doi: 10.1111/bjd.18328. [Epub ahead of print] No abstract available.

PMID:
31278742
13.

Discoidin domain receptors: A promising target in melanoma.

Reger de Moura C, Battistella M, Sohail A, Caudron A, Feugeas JP, Podgorniak MP, Pages C, Mazouz Dorval S, Marco O, Menashi S, Fridman R, Lebbé C, Mourah S, Jouenne F.

Pigment Cell Melanoma Res. 2019 Sep;32(5):697-707. doi: 10.1111/pcmr.12809. Epub 2019 Jul 22.

PMID:
31271515
14.

Efficacy and safety of brentuximab vedotin plus bendamustine in advanced-stage primary cutaneous T-cell lymphomas.

Dumont M, Ram-Wolff C, Roelens M, Brice P, Peffault de Latour R, Battistella M, Madelaine I, Delyon J, Herms F, Bouaziz JD, Moins-Teisserenc H, Lebbé C, Bagot M, de Masson A.

Br J Dermatol. 2019 Jun 17. doi: 10.1111/bjd.18215. [Epub ahead of print] No abstract available.

PMID:
31206589
15.

Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.

Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, Rutkowski P, Nathan PD, Ribas A, Davies MA, Flaherty KT, Burgess P, Tan M, Gasal E, Voi M, Schadendorf D, Long GV.

N Engl J Med. 2019 Aug 15;381(7):626-636. doi: 10.1056/NEJMoa1904059. Epub 2019 Jun 4.

PMID:
31166680
16.

Diagnosis and treatment of Kaposi's sarcoma: European consensus-based interdisciplinary guideline (EDF/EADO/EORTC).

Lebbe C, Garbe C, Stratigos AJ, Harwood C, Peris K, Marmol VD, Malvehy J, Zalaudek I, Hoeller C, Dummer R, Forsea AM, Kandolf-Sekulovic L, Olah J, Arenberger P, Bylaite-Bucinskiene M, Vieira R, Middleton M, Levy A, Eggermont AM, Battistella M, Spano JP, Grob JJ, Pages C; European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO) and the European Organisation for Research and Treatment of Cancer (EORTC).

Eur J Cancer. 2019 Jun;114:117-127. doi: 10.1016/j.ejca.2018.12.036. Epub 2019 May 13.

PMID:
31096150
17.

Severe gastrointestinal toxicity of MEK inhibitors.

Mourad N, Lourenço N, Delyon J, Eftekhari P, Bertheau P, Allayous C, Ballon A, Pagès C, Allez M, Lebbé C, Baroudjian B; PATIO group.

Melanoma Res. 2019 Oct;29(5):556-559. doi: 10.1097/CMR.0000000000000618.

PMID:
31095035
18.

Acquired generalized lipodystrophy under immune checkpoint inhibition.

Haddad N, Vidal-Trecan T, Baroudjian B, Zagdanski AM, Arangalage D, Battistella M, Gautier JF, Lebbe C, Delyon J; PATIO group.

Br J Dermatol. 2019 May 11. doi: 10.1111/bjd.18124. [Epub ahead of print]

PMID:
31077337
19.

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase.

JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425.

PMID:
31042256
20.

Rechallenge of immune checkpoint inhibitor after pembrolizumab-induced myasthenia gravis.

Tedbirt B, De Pontville M, Branger P, Picard C, Baroudjian B, Lebbé C, Carpentier AF, Delyon J; PATIO group.

Eur J Cancer. 2019 May;113:72-74. doi: 10.1016/j.ejca.2019.03.006. Epub 2019 Apr 12. No abstract available.

PMID:
30986705
21.

Usefulness of the 'two-step method' of digital follow-up for early-stage melanoma detection in high-risk French patients: a retrospective 4-year study.

Gasparini G, Madjlessi N, Delyon J, Carmisciano L, Brahimi N, Basset-Seguin N, Oren M, Battistella M, Lebbé C, Herms F, Baroudjian B.

Br J Dermatol. 2019 Aug;181(2):415-416. doi: 10.1111/bjd.18006. Epub 2019 May 12. No abstract available.

PMID:
30977907
22.

RASA1 loss in a BRAF-mutated Langerhans cell sarcoma: a mechanism of resistance to BRAF inhibitor.

Jouenne F, Reger de Moura C, Lorillon G, Meignin V, Dumaz N, Lebbe C, Mourah S, Tazi A.

Ann Oncol. 2019 Jul 1;30(7):1170-1172. doi: 10.1093/annonc/mdz125. No abstract available.

PMID:
30977771
23.

Heterogeneity of PD-L1 expression and CD8 tumor-infiltrating lymphocytes among subtypes of cutaneous adnexal carcinomas.

Duverger L, Osio A, Cribier B, Mortier L, De Masson A, Basset-Seguin N, Lebbé C, Battistella M.

Cancer Immunol Immunother. 2019 Jun;68(6):951-960. doi: 10.1007/s00262-019-02334-8. Epub 2019 Apr 5.

PMID:
30953116
24.

Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.

Basse C, Italiano A, Penel N, Mir O, Chemin C, Toulmonde M, Duffaud F, Le Cesne A, Chevreau C, Maynou C, Anract P, Gouin F, Rios M, Firmin N, Kurtz JE, Kerbrat P, Piperno-Neumann S, Bertucci F, Rosset P, Isambert N, Bompas E, Dubray-Longeras P, Fiorenza F, Le Maignan C, Chaigneau L, Thyss A, Bouché O, Eymard JC, Delcambre Lair C, Adam J, Karanian M, Lebbé C, Dupré A, Meeus P, Brahmi M, Dufresne A, Ducimetière F, Ray-Coquard I, Blay JY.

Int J Cancer. 2019 Oct 15;145(8):2135-2143. doi: 10.1002/ijc.32307. Epub 2019 Apr 15.

25.

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C.

Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22.

PMID:
30909072
26.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
27.

Management of Kaposi sarcoma after solid organ transplantation: A European retrospective study.

Delyon J, Rabate C, Euvrard S, Harwood CA, Proby C, Güleç AT, Seçkin D, Del Marmol V, Bouwes-Bavinck JN, Ferrándiz-Pulido C, Ocampo MA, Barete S, Legendre C, Francès C, Porcher R, Lebbe C; Skin Care in Organ Transplant Patients Europe (SCOPE) group.

J Am Acad Dermatol. 2019 Aug;81(2):448-455. doi: 10.1016/j.jaad.2019.03.028. Epub 2019 Mar 19.

PMID:
30902727
28.

A targeted genomic alteration analysis predicts survival of melanoma patients under BRAF inhibitors.

Louveau B, Delyon J, De Moura CR, Battistella M, Jouenne F, Golmard L, Sadoux A, Podgorniak MP, Chami I, Marco O, Caramel J, Dalle S, Feugeas JP, Dumaz N, Lebbe C, Mourah S.

Oncotarget. 2019 Mar 1;10(18):1669-1687. doi: 10.18632/oncotarget.26707. eCollection 2019 Mar 1.

29.

Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients.

Gauci ML, Boudou P, Squara PA, Delyon J, Allayous C, Mourah S, Resche-Rigon M, Lebbé C, Baroudjian B, Gautier JF; PATIO group.

Melanoma Res. 2019 Jun;29(3):328-332. doi: 10.1097/CMR.0000000000000585.

PMID:
30817442
30.

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.

Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, Schadendorf D, Ajaz M, Svane IM, Gonzalez R, Rollin L, Lord-Bessen J, Saci A, Grigoryeva E, Pigozzo J.

J Clin Oncol. 2019 Apr 10;37(11):867-875. doi: 10.1200/JCO.18.01998. Epub 2019 Feb 27.

31.

Refractory hypotension with fever revealing checkpoint inhibitor-induced hypophysitis.

Plaçais L, Hau E, Delyon J, Azoulay E, Gautier JF, Lebbé C, Baroudjian B; PATIO Group.

Melanoma Res. 2019 Apr;29(2):205-207. doi: 10.1097/CMR.0000000000000517.

PMID:
30801428
32.

Successful Treatment of Generalized Eruptive Keratoacanthoma of Grzybowski with Acitretin.

Mascitti H, De Masson A, Brunet-Possenti F, Bouaziz JD, Laly P, Mourad N, Garrigues JM, Laurent-Roussel S, Cavelier-Balloy B, Moulonguet I, Leschi C, Mourah S, Bagot M, Lebbé C, Basset-Seguin N.

Dermatol Ther (Heidelb). 2019 Jun;9(2):383-388. doi: 10.1007/s13555-019-0287-0. Epub 2019 Feb 21.

33.

Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.

D'Angelo SP, Hunger M, Brohl AS, Nghiem P, Bhatia S, Hamid O, Mehnert JM, Terheyden P, Shih KC, Brownell I, Lebbé C, Lewis KD, Linette GP, Milella M, Schlichting M, Hennessy MH, Bharmal M.

Cancer Immunol Immunother. 2019 Apr;68(4):609-618. doi: 10.1007/s00262-018-02295-4. Epub 2019 Feb 5.

34.

Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.

Gutzmer R, Harrington KJ, Hoeller C, Lebbé C, Malvehy J, Öhrling K, Downey G, Dummer R.

Eur J Dermatol. 2018 Dec 1;28(6):736-749. doi: 10.1684/ejd.2018.3447. Review.

PMID:
30698145
35.

New perspectives in Merkel cell carcinoma.

Del Marmol V, Lebbé C.

Curr Opin Oncol. 2019 Mar;31(2):72-83. doi: 10.1097/CCO.0000000000000508.

PMID:
30694842
36.

CRTC1-TRIM11 Fusion in a Case of Metastatic Clear Cell Sarcoma: Are CRTC1-TRIM11 Fusion-bearing Tumors Melanocytomas or Clear Cell Sarcomas?

Bontoux C, Baroudjian B, Le Maignan C, Vercellino L, Farges C, Guillemot D, Pierron G, Lebbé C, Battistella M.

Am J Surg Pathol. 2019 Jun;43(6):861-863. doi: 10.1097/PAS.0000000000001217. No abstract available.

PMID:
30676334
37.

New Vision in Photoprotection and Photorepair.

Leccia MT, Lebbe C, Claudel JP, Narda M, Basset-Seguin N.

Dermatol Ther (Heidelb). 2019 Mar;9(1):103-115. doi: 10.1007/s13555-019-0282-5. Epub 2019 Jan 23. Review.

38.

[Update in treatment for Merkel Cell Carcinoma and clinical practice guide].

Tétu P, Baroudjian B, Madelaine I, Delyon J, Lebbé C.

Bull Cancer. 2019 Jan;106(1):64-72. doi: 10.1016/j.bulcan.2018.11.009. Epub 2018 Dec 19. Review. French.

PMID:
30579571
39.

Management of immune-related adverse events resulting from immune checkpoint blockade.

Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group.

Expert Rev Anticancer Ther. 2019 Mar;19(3):209-222. doi: 10.1080/14737140.2019.1562342. Epub 2019 Jan 9.

PMID:
30572735
40.

Letter to the Editor: Could Immunogenicity of Kaposi Sarcoma Be More Linked to Viral Antigens Than to the Tumor Mutational Burden?

Delyon J, Arangalage D, Baroudjian B, Lebbe C.

J Natl Compr Canc Netw. 2018 Dec;16(12):1418-1419. doi: 10.6004/jnccn.2018.7088. No abstract available.

PMID:
30545987
41.

Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial.

Ascierto PA, Long GV, Robert C, Brady B, Dutriaux C, Di Giacomo AM, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Ny L, Arance A, Svane IM, Schadendorf D, Gogas H, Saci A, Jiang J, Rizzo J, Atkinson V.

JAMA Oncol. 2019 Feb 1;5(2):187-194. doi: 10.1001/jamaoncol.2018.4514.

PMID:
30422243
42.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
43.

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I.

Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29.

PMID:
30384014
44.

Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review.

Charpentier C, Delyon J, Glotz D, Peraldi MN, Rerolle JP, Barrou B, Ducroux E, Coilly A, Legeai C, Barete S, Lebbé C.

Transplantation. 2019 Jan;103(1):e22-e28. doi: 10.1097/TP.0000000000002468. Review.

PMID:
30273235
45.

Nivolumab-induced alopecia areata: A reversible factor of good prognosis?

Lakhmiri M, Cavelier-Balloy B, Lacoste C, Cassius C, Baroudjian B, Delyon J, Lebbé C, Reygagne P.

JAAD Case Rep. 2018 Sep 14;4(8):761-765. doi: 10.1016/j.jdcr.2018.05.022. eCollection 2018 Sep. No abstract available.

46.

Immune checkpoint inhibitor rechallenge in patients with immune-related myositis.

Delyon J, Brunet-Possenti F, Leonard-Louis S, Arangalage D, Baudet M, Baroudjian B, Lebbe C, Hervier B; PATIO Group.

Ann Rheum Dis. 2019 Nov;78(11):e129. doi: 10.1136/annrheumdis-2018-214336. Epub 2018 Sep 21. No abstract available.

PMID:
30242031
47.

Enteritis without colitis in patients treated with immune checkpoint inhibitors: a tricky diagnosis.

Sokal A, de Chou CS, Delyon J, Roche B, Lourenco N, Lebbé C, Baroudjian B; PATIO group.

Melanoma Res. 2018 Oct;28(5):483-484. doi: 10.1097/CMR.0000000000000484. No abstract available.

PMID:
30148767
48.

Osteopenia and fractures associated with long-term therapy with MEK inhibitors.

Dumas M, Laly P, Gottlieb J, Vercellino L, Paycha F, Bagot M, Baroudjian B, Madelaine I, Basset-Seguin N, Eftekhari P, Pagès C, Lebbé C, Lioté F.

Melanoma Res. 2018 Dec;28(6):641-644. doi: 10.1097/CMR.0000000000000490.

PMID:
30124538
49.

Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients.

Zehou O, Leibler C, Arnault JP, Sayegh J, Montaudié H, Rémy P, Glotz D, Cordonnier C, Martin L, Lebbé C.

Am J Transplant. 2018 Dec;18(12):3065-3071. doi: 10.1111/ajt.15071. Epub 2018 Sep 21.

PMID:
30107088
50.

Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic.

Baurain JF, Robert C, Mortier L, Neyns B, Grange F, Lebbe C, Ulloa-Montoya F, De Sousa Alves PM, Gillet M, Louahed J, Jarnjak S, Lehmann FF.

ESMO Open. 2018 Jul 25;3(5):e000384. doi: 10.1136/esmoopen-2018-000384. eCollection 2018.

Supplemental Content

Support Center